277 related articles for article (PubMed ID: 34957601)
1. Effective low-dose sirolimus regimen for kaposiform haemangioendothelioma with Kasabach-Merritt phenomenon in young infants.
Harbers VEM; van der Salm N; Pegge SAH; van der Vleuten CJM; Verhoeven BH; Vrancken SLAG; Schultze Kool LJ; Fuijkschot J; Te Loo DMMWM
Br J Clin Pharmacol; 2022 Jun; 88(6):2769-2781. PubMed ID: 34957601
[TBL] [Abstract][Full Text] [Related]
2. Retroperitoneal kaposiform hemangioendothelioma complicated by Kasabach-Merritt phenomenon and obstructive jaundice: A retrospective series of 3 patients treated with sirolimus.
Yao W; Li K; Wang Z; Dong K; Zheng S
Pediatr Dermatol; 2020 Jul; 37(4):677-680. PubMed ID: 32212177
[TBL] [Abstract][Full Text] [Related]
3. Sirolimus for Kaposiform Hemangioendothelioma With Kasabach-Merritt Phenomenon in Two Infants.
Wang Y; Kong L; Sun B; Cui J; Shen W
J Craniofac Surg; 2020 Jun; 31(4):1074-1077. PubMed ID: 32176003
[TBL] [Abstract][Full Text] [Related]
4. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon in an infant: Successful treatment with prednisolone, vincristine, and addition of sirolimus.
Cashell J; Smink GM; Helm K; Xavier F
Pediatr Blood Cancer; 2018 Dec; 65(12):e27305. PubMed ID: 30070028
[TBL] [Abstract][Full Text] [Related]
5. Sirolimus for treatment of Kaposiform haemangioendothelioma with Kasabach-Merritt phenomenon: a retrospective cohort study.
Zhang G; Chen H; Gao Y; Liu Y; Wang J; Liu XY
Br J Dermatol; 2018 May; 178(5):1213-1214. PubMed ID: 29388191
[No Abstract] [Full Text] [Related]
6. Sirolimus combined with glucocorticoids in the treatment of Kasabach-Merritt phenomenon in a neonate: A case report.
Cheng J; Zou Y; Fu R; Jin P; Huang M; Wu Z; Bai H; Huang X; Yuan H
Medicine (Baltimore); 2024 Apr; 103(14):e37706. PubMed ID: 38579031
[TBL] [Abstract][Full Text] [Related]
7. Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: A multicenter retrospective study.
Ji Y; Chen S; Xiang B; Li K; Xu Z; Yao W; Lu G; Liu X; Xia C; Wang Q; Li Y; Wang C; Yang K; Yang G; Tang X; Xu T; Wu H
Int J Cancer; 2017 Aug; 141(4):848-855. PubMed ID: 28486787
[TBL] [Abstract][Full Text] [Related]
8. Vincristine and sirolimus in the treatment of kaposiform haemangioendothelioma.
Peng S; Yang K; Xu Z; Chen S; Ji Y
J Paediatr Child Health; 2019 Sep; 55(9):1119-1124. PubMed ID: 30604513
[TBL] [Abstract][Full Text] [Related]
9. Sirolimus as initial therapy for kaposiform hemangioendothelioma and tufted angioma.
Wang H; Guo X; Duan Y; Zheng B; Gao Y
Pediatr Dermatol; 2018 Sep; 35(5):635-638. PubMed ID: 29999213
[TBL] [Abstract][Full Text] [Related]
10. [Refractory kaposiforme hemangioendothelioma in the pediatric population: case report and literature review.].
Gómez-Villegas CP; Pérez-Téllez C; Ochoa-Gaviria J; Builes N
Bol Med Hosp Infant Mex; 2021; 78(4):376-384. PubMed ID: 34351887
[TBL] [Abstract][Full Text] [Related]
11. Sirolimus therapy for kaposiform hemangioendothelioma with long-term follow-up.
Wang Z; Yao W; Sun H; Dong K; Ma Y; Chen L; Zheng S; Li K
J Dermatol; 2019 Nov; 46(11):956-961. PubMed ID: 31489702
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of Kasabach-Merritt phenomenon arising from Kaposiform hemangioendothelioma by sirolimus.
Wang Z; Li K; Dong K; Xiao X; Zheng S
J Pediatr Hematol Oncol; 2015 Jan; 37(1):72-3. PubMed ID: 24309604
[No Abstract] [Full Text] [Related]
13. Additive value of transarterial embolization to systemic sirolimus treatment in kaposiform hemangioendothelioma.
Brill R; Uller W; Huf V; Müller-Wille R; Schmid I; Pohl A; Häberle B; Perkowski S; Funke K; Till AM; Lauten M; Neumann J; Güttel C; Heid E; Ziermann F; Schmid A; Hüsemann D; Meyer L; Sporns PB; Schinner R; Schmidt VF; Ricke J; Rössler J; Kapp FG; Wohlgemuth WA; Wildgruber M
Int J Cancer; 2021 May; 148(9):2345-2351. PubMed ID: 33231291
[TBL] [Abstract][Full Text] [Related]
14. A Case Report of 2 Sirolimus-Related Deaths Among Infants With Kaposiform Hemangioendotheliomas.
Ying H; Qiao C; Yang X; Lin X
Pediatrics; 2018 Apr; 141(Suppl 5):S425-S429. PubMed ID: 29610165
[TBL] [Abstract][Full Text] [Related]
15. Development of Kasabach-Merritt phenomenon following vaccination: More than a coincidence?
Ji Y; Chen S; Yang K; Xia C; Peng S
J Dermatol; 2018 Oct; 45(10):1203-1206. PubMed ID: 30118141
[TBL] [Abstract][Full Text] [Related]
16. Sirolimus, a promising treatment for refractory Kaposiform hemangioendothelioma.
Kai L; Wang Z; Yao W; Dong K; Xiao X
J Cancer Res Clin Oncol; 2014 Mar; 140(3):471-6. PubMed ID: 24464150
[TBL] [Abstract][Full Text] [Related]
17. A case of kaposiform haemangioendothelioma successfully and safely treated with sirolimus.
Wlodek C; Burt H; Shaw L
Clin Exp Dermatol; 2017 Oct; 42(7):825-827. PubMed ID: 28703334
[No Abstract] [Full Text] [Related]
18. NEWBORNS WITH KASABACH-MERRITT PHENOMENON-ASSOCIATED KAPOSIFORM HEMANGIOENDOTHELIOMA: A REPORT OF 6 CASES.
Benzar IM; Rebenkov SO; Levytskyi AF; Fedoniuk LY; Fomina LV; Sas LM; Stravskyy TY
Wiad Lek; 2020; 73(8):1785-1789. PubMed ID: 33055352
[TBL] [Abstract][Full Text] [Related]
19. Kaposiform haemangioendothelioma in an adult: lack of response to topical sirolimus and response to radiotherapy.
Der Sarkissian SA; Wong XL; Kossard S; Hong A; Sebaratnam DF
Clin Exp Dermatol; 2022 Jan; 47(1):192-193. PubMed ID: 34480811
[TBL] [Abstract][Full Text] [Related]
20. The effect of topical sirolimus on superficial Kaposiform haemangioendothelioma.
Liu YX; Zhang J; Nie XL; Chen YL; Wang ZY; Xu ZG
Australas J Dermatol; 2021 May; 62(2):e329-e331. PubMed ID: 33216947
[No Abstract] [Full Text] [Related]
[Next] [New Search]